Non-selective group I/group II metabotropic glutamate receptor antagonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1.1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 209.2. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.78 mL||23.9 mL||47.8 mL|
|5 mM||0.96 mL||4.78 mL||9.56 mL|
|10 mM||0.48 mL||2.39 mL||4.78 mL|
|50 mM||0.1 mL||0.48 mL||0.96 mL|
References are publications that support the products' biological activity.
Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333 PMID: 7992387
Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195 PMID: 8381746
Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970 PMID: 7751958
If you know of a relevant reference for (RS)-MCPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-MCPG, supplier, Non-Selective, mGlur, antagonists, Group, I, II, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, (Metabotropic), Group, I, Receptors, Glutamate, (Metabotropic), Group, II, Receptors, Glutamate, (Metabotropic), Group, I, Receptors, Tocris Bioscience
11 Citations for (RS)-MCPG
Citations are publications that use Tocris products. Selected citations for (RS)-MCPG include:
Zhang and Lisman (2012) Activity-dependent regulation of synaptic strength by PSD-95 in CA1 neurons. Cereb Cortex 107 1058 PMID: 22114157
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Takayasu et al (2006) Glial glutamate transporters maintain one-to-one relationship at the climbing fiber-Purkinje cell synapse by preventing glutamate spillover. J Neurophysiol 26 6563 PMID: 16775144
Ohba et al (2005) BDNF locally potentiates GABAergic presynaptic machineries: target-selective circuit inhibition. Proc Natl Acad Sci U S A 15 291 PMID: 15238431
Zhuo et al (1999) On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus. Learn Mem 5 467 PMID: 10489262
Tronson et al (2010) Metabotropic glutamate receptor 5/Homer interactions underlie stress effects on fear. J Neurosci 68 1007 PMID: 21075228
Shankar et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 837 PMID: 18568035
Petzold et al (2008) Coupling of neural activity to blood flow in olfactory glomeruli is mediated by astrocytic pathways. Biol Psychiatry 58 897 PMID: 18579080
Muddashetty et al (2007) Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27 5338 PMID: 17507556
Jan and Westbrook (2007) Disynaptic amplification of metabotropic glutamate receptor 1 responses in the olfactory bulb. J Neurosci 27 132 PMID: 17202480
Do you know of a great paper that uses (RS)-MCPG from Tocris? If so please let us know.
Reviews for (RS)-MCPG
There are currently no reviews for this product. Be the first to review (RS)-MCPG and earn rewards!
Have you used (RS)-MCPG?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.